Cargando…

Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors

Immune checkpoint inhibitors (ICIs) can block distinct receptors on T cells or tumor cells thus preventing T cell inactivation and tumor immune escape. While the clinical response to treatment with ICIs in cancer patients is impressive, this therapy is often associated with a number of immune-relate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reul, Johanna, Frisch, Janina, Engeland, Christine E., Thalheimer, Frederic B., Hartmann, Jessica, Ungerechts, Guy, Buchholz, Christian J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382738/ https://www.ncbi.nlm.nih.gov/pubmed/30838171 http://dx.doi.org/10.3389/fonc.2019.00052

Ejemplares similares

GluA4-Targeted AAV Vectors Deliver Genes Selectively to Interneurons while Relying on the AAV Receptor for Entry
por: Hartmann, Jessica, et al.
Publicado: (2019)

Measles Virus as an Oncolytic Immunotherapy
por: Engeland, Christine E., et al.
Publicado: (2021)

Engineered AAV vectors for improved central nervous system gene delivery
por: A Kotterman, Melissa, et al.
Publicado: (2015)

Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory
por: Veinalde, Rūta, et al.
Publicado: (2021)

Plectin-1 Targeted AAV Vector for the Molecular Imaging of Pancreatic Cancer
por: Konkalmatt, Prasad R., et al.
Publicado: (2013)

AAV vectors engineered to target insulin receptor greatly enhance intramuscular gene delivery
por: Jackson, Cody B., et al.
Publicado: (2020)

AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma
por: Strecker, M.I., et al.
Publicado: (2022)

Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics
por: Kontermann, Roland E., et al.
Publicado: (2021)

AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6
por: Denard, Jérôme, et al.
Publicado: (2018)

TGF‐β gene transfer and overexpression via rAAV vectors stimulates chondrogenic events in human bone marrow aspirates
por: Frisch, Janina, et al.
Publicado: (2016)

Effective delivery of large genes to the retina by dual AAV vectors
por: Trapani, Ivana, et al.
Publicado: (2014)

Evaluation of P2X7 Receptor Function in Tumor Contexts Using rAAV Vector and Nanobodies (AAVnano)
por: Demeules, Mélanie, et al.
Publicado: (2020)

Impact of mechanical stimulation on the chondrogenic processes in human bone marrow aspirates modified to overexpress sox9 via rAAV vectors
por: Venkatesan, Jagadeesh K., et al.
Publicado: (2017)

T Cell-Mediated Immune Responses to AAV and AAV Vectors
por: Ertl, Hildegund C. J.
Publicado: (2021)

Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics
por: Charitidis, Filippos T., et al.
Publicado: (2021)

Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics
por: Charitidis, Filippos T., et al.
Publicado: (2022)

Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye
por: Li, Wensheng, et al.
Publicado: (2009)

CD62L as target receptor for specific gene delivery into less differentiated human T lymphocytes
por: Kapitza, Laura, et al.
Publicado: (2023)

A Library-Based Screening Strategy for the Identification of DARPins as Ligands for Receptor-Targeted AAV and Lentiviral Vectors
por: Hartmann, Jessica, et al.
Publicado: (2018)

A Library-Based Screening Strategy for the Identification of DARPins as Ligands for Receptor-Targeted AAV and Lentiviral Vectors
por: Hartmann, Jessica, et al.
Publicado: (2021)

Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy
por: Kashiwakura, Yuji, et al.
Publicado: (2023)

Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors
por: Kay, Christine N., et al.
Publicado: (2013)

Enhanced Cancer Therapy Using an Engineered Designer Cytokine Alone and in Combination With an Immune Checkpoint Inhibitor
por: Pradhan, Anjan K., et al.
Publicado: (2022)

Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists
por: Backhaus, Paul S., et al.
Publicado: (2019)

Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice
por: Iwata, Nobuhisa, et al.
Publicado: (2013)

AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System
por: Marino, Marika, et al.
Publicado: (2022)

In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery
por: Breuer, Cort B., et al.
Publicado: (2020)

Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors
por: Wang, Qizhao, et al.
Publicado: (2016)

Correction: Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors
por: Kay, Christine N., et al.
Publicado: (2013)

Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More
por: Ellithi, Moataz, et al.
Publicado: (2020)

A Review of Hodgkin Lymphoma in the Era of Checkpoint Inhibitors
por: Schimmoeller, Christopher J, et al.
Publicado: (2023)

Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
por: Bartel, Melissa, et al.
Publicado: (2011)

Gene Delivery to Adipose Tissue Using Transcriptionally Targeted rAAV8 Vectors
por: Uhrig-Schmidt, Silke, et al.
Publicado: (2014)

Innate Immune Responses to AAV Vectors
por: Rogers, Geoffrey L., et al.
Publicado: (2011)

AAV Vectored Immunoprophylaxis for Filovirus Infections
por: Rghei, Amira D., et al.
Publicado: (2020)

AAV gene therapy vectors in the TMJ
por: Brouxhon, Sabine M., et al.
Publicado: (2022)

A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors
por: Floerchinger, Alessia, et al.
Publicado: (2023)

Targeting the somatosensory system with AAV9 and AAV2retro viral vectors
por: Skorput, Alexander G. J., et al.
Publicado: (2022)

Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems
por: Chan, Ken Y, et al.
Publicado: (2017)

CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector
por: Murlidharan, Giridhar, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v562olbcshbglt8fdfjeetl0up